The Summary
This randomized, double-blind, placebo-controlled crossover study evaluated cannabinol (CBN) for insomnia. Twenty adults with diagnosed insomnia received a single oral dose of 30 mg or 300 mg of CBN, or a placebo, on separate nights. While CBN did not significantly reduce wakefulness after sleep onset (the primary outcome), the 300 mg dose significantly reduced the time it took to fall asleep, improved self-reported sleep quality, increased non-rapid eye movement-2 sleep, and reduced brain arousals. Mild-to-moderate adverse events were common, indicating a need for larger, longer trials.
Why this is interesting
CBN is widely marketed as a natural aid, but scientific proof of its effectiveness was lacking. This study provides the first objective clinical trial evidence that high-dose CBN can actually help people fall asleep faster and improve perceived quality, even though it didn't keep them asleep longer. For consumers, it means CBN might finally be a scientifically backed option for occasional restlessness, though we still need larger trials to confirm its safety and long-term effectiveness.